scholarly journals Establishment of TRAIL-Resistance Kasumi-1 Cell Line and the Analysis of It different mRNA Expression Profile with the Original Kasumi-1 Cell Line

Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 5221-5221
Author(s):  
Xuewei Jiang ◽  
Pan Zengkai ◽  
Chen Jin ◽  
Yu Pengfei ◽  
Li-Gen Liu

Abstract Introduction Tumor necrosis factor related apoptosis inducing ligand (TRAIL) can induce the apoptosis of many human leukemia cells while sparing of normal cells, but its resistance is also universal. Our previous study on apoptosis of t(8;21) positive acute myeloid leukemia cell line Kasumi-1 induced by rhTRAIL showed that the survival rate no longer decreased significantly when rsTRAIL reached a certain concentration which implied Kasumi-1 cells might have a resistant tendency to TRAIL. Then, we established a TRAIL-resistant Kasumi-1 cell line (Kasumi-1 TR) by intermittently escalating rsTRAIL concentration in culture media, and compared the mRNA expression profile with the original Kasumi-1 cell line by using Affymetrix Human Genome U133 Plus 2.0 Array. Methods Kasumi-1 TR cell line was established by intermittently treated Kasumi-1 cells with progressively escalating rsTRAIL concentration. Proliferation of leukemia cells were measured by CCK-8 assay, and rsTRAIL IC50 of cells and resistance index were calculated according to proliferation of cells treated with rsTRAIL at different concentrations. TRAIL and TRAIL receptors 1-4 on cells surface were detected by flow cytometry. Expression profiles of Kasumi-1 cells and Kasumi-1 TR cells were analyzed by Affymetrix Human Genome U133 Plus 2.0 Array to identify differentially expressed genes, and the search of genes possibly related with TRAIL-resistance were using by GO functional analysis and pathway enrichment analysis. Results 1) Kasumi-1 TR cells proliferation was faster than that of Kasumi-1 cells(Fig 1A); 2) IC50 of 24 hours for Kasumi-1 cells was 756.833ng/ml (logIC50 2.879 ± 0.148), IC50 of 24 hours for Kasumi-1 TR cells was 1634646.005ng/ ml (logIC50 6.213 ± 0.637), the RI of 24h was 2159 (Fig 1B); IC50 of 48 hours for Kasumi-1 cells was 345.390ng/ml (logIC50 2.538 ± 0.153), IC50 of 48 hours for Kasumi-1 TR cells was 33642.641ng/ml (logIC50 is 4.257 ± 0.317), the RI for 48h was 97 (Fig 1C); 3) Cell surface expression of TRAIL and its receptors 1-4 had no difference between two cell lines(Fig 1D). 4) There were 1537 genes up regulated by more than 2 times while 487 genes down regulated by more than 2 times in Kasumi-1 TR cells compared with the original Kasumi-1 cells (Fig 1E). Of which BCL-2 family antiapoptotic gene BCL2 is increased by 3.153 times and BCL2A1 increased by 18.23 times, IFNAR1 involved in JAK/STAT pathway increased by 12.841 times and TRAIL death receptor TNFRSF10A down regulated by 3.256 times(Fig 1F). Conclusions: The Kasumi-1 cell line with rsTRAIL resistance (Kasumi-1 TR) is established, and its resistance may be associated with the up expression of BCL2, BCL2A1, IFNAR1 and down regulated expression of DR4. Acknowledgment This work was supported by grants from NSFC (30672415) and STCSM (054119528). Figure 1 Figure 1. Disclosures No relevant conflicts of interest to declare.

10.1038/14313 ◽  
1999 ◽  
Vol 23 (S3) ◽  
pp. 47-47
Author(s):  
Kishorchandra Gohil ◽  
Lester Packer ◽  
Nathanael Gray ◽  
Gustavo Rafael Rosania ◽  
Ronald K. Moy ◽  
...  

2019 ◽  
Vol 20 (8) ◽  
pp. 1967
Author(s):  
You-Ri Lee ◽  
Eunjoo Hwang ◽  
Young-Ju Jang

The tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces cancer cell death with minimal damage to normal cells; however, some cancer cells are resistant to TRAIL. TRAIL resistance may be overcome by agonistic antibodies to TRAIL receptors. In this study, we report the toxic effects of a novel recombinant agonistic human anti–TRAIL receptor 1 (DR4) monoclonal antibody Fab fragment, DR4-4, on various TRAIL-resistant and -sensitive cancer cell lines. The mechanisms of DR4-4 Fab–induced cell death in a human T cell leukemia cell line (Jurkat) were investigated using cell viability testing, immunoblotting, immunoassays, flow cytometry, and morphological observation. DR4-4 Fab–induced caspase-independent necrosis was observed to occur in Jurkat cells in association with p38 mitogen-activated protein kinase activation, cellular FLICE (FADD-like IL-1β-converting enzyme)-inhibitory protein degradation, decreased mitochondrial membrane potential, and increased mitochondrial reactive oxygen species production. Increased cytotoxic effects of DR4-4 Fab were observed in combination with TRAIL or γ-irradiation. Our results indicate that the novel DR4-4 Fab might overcome TRAIL-resistance and induce death in leukemia cells via cellular mechanisms different from those activated by TRAIL. DR4-4 Fab may have application as a potential therapeutic antibody fragment in single or combination therapy for cancer.


Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 3790-3790
Author(s):  
Pavel Klener ◽  
Jan Molinsky ◽  
Marie Markova ◽  
Sergiu Leahomschi ◽  
Tereza Simonova ◽  
...  

Abstract Abstract 3790 Poster Board III-726 TNF-related apoptosis inducing ligand (TRAIL) is a death ligand with selective antitumor activity and minimal cytotoxicity toward non-malignant tissues. TRAIL is under evaluation in several clinical trials in the treatment of diverse cancers, including hematologic malignancies. Molecular mechanisms responsible for acquired TRAIL resistance (e.g. following treatment with TRAIL) are largely unknown. TRAIL-sensitive T-lymphoblastic leukemia cell line Jurkat was cultivated for 8 weeks with TRAIL (1mg/mL). Three TRAIL-resistant Jurkat subclones (TR1-3) were derived and subjected to analysis. Acquired TRAIL-resistance was asociated with decreased sensitivity to several of the tested cytotoxic agents (including TNF-alpha, Fas-ligand, fludarabine and methotrexate), while sensitivity to other agents was unchanged (doxorubicin, cisplatin, etoposid) or even increased (cytarabine). TRAIL-resistant subclones did not show significant differences either in the cell surface expression of death ligand receptors (TRAIL-R1-4, TNF-R, Fas) or in the protein levels of key antiapoptotic regulators (e.g. Bcl2, Mcl1, XIAP, Survivin). Surprisingly, the most prominent finding was significant upregulation of apical proapoptotic caspase 10 (CASP10) in subclone TR1 on mRNA (3-fold increase) as well as on protein level. Moreover, downregulation of CASP8 was detected in subclone TR1 both by western blotting and real-time RT-PCR. siRNA-induced inhibition of protein CASP10 in subclone TR1 was associated with partial restoration of sensitivity to TRAIL-induced apoptosis. No relevant mutations were revealed by sequencing of CASP10 transcript variants A and D of TR1 subclone compared to TRAIL-sensitive Jurkat cells. Immunoprecipitation (IP) analysis of death-inducing signaling complex (DISC) using biotinylated TRAIL suggested impaired DICS formation in subclones TR2 and TR3, but not in TR1. DISC analysis also demonstrated that CASP10 was physically bound in the DISC of TR1 subclone after exposure to TRAIL. Preincubation of the TR subclones with several histone-deacetylase inhibitors (HDACi: vorinostat, sodium valproate or sodium butyrate) for 12 hours almost completely restored sensitivity to TRAIL. Immunoprecipitation analysis of DISC showed treatment with HDACi for 12h resulted in substantially increased binding of precleaved CASP8 (55kD and 43kD) and precleaved CASP10 (53kD) to the DISC. In subclone TR1 pretreatment with HDACi was associated with downregulation of overexpresssed CASP10 mRNA to the levels detected in the original Jurkat cell line. Genome-wide gene-expression profiling using Illumina chips unveiled additional changes in the transcriptome associated with acquired TRAIL resistance. Across all microarrays, the most statistically significant gene expression change was upregulation of Midkine, a heparin-binding growth factor presumably involved in the protection of cancer cells against TRAIL. We showed that acquired TRAIL resistance of Jurkat T-lymphoblastic leukemia cells was associated with complex disruption of both extrinsic and intrinsic apoptotic pathways. While impaired formation of DISC appeared a major molecular mechanism underlying the death-ligand resistance of subclones TR2-3, deregulated expression of apical caspases 8 and 10 substantially contributed to resistance of subclone TR1. RNA interference experiments demonstrated downregulation of otherwise proapoptotic CASP10 functionally impaired extrinsic apoptotic pathway and results in increase apoptotic response to TRAIL. We speculate that displacement of CASP8 by overexpressed CASP10 from DISC might partially block downstream conveying of the proapoptotic signaling from aggregated death receptors. The microarray data implicated that additional molecular deregulations (e.g. overexpression of midkine) associated with acquired TRAIL resistance might contribute to the “multi-drug” resistant phenotype of TRAIL-resistant subclones. The ability of HDACi to restore sensitivity of TRAIL-resistant Jurkat subclones to TRAIL might influence design of novel experimental strategies in the treatment of cancer. Financial Support: LC 06044, MSM 0021620806, MSM 0021620808, GAUK 2009/259153/86309, GAUK 259211/110709 Disclosures: No relevant conflicts of interest to declare.


2012 ◽  
Vol 508 (1) ◽  
pp. 4-8 ◽  
Author(s):  
Filippo Martinelli-Boneschi ◽  
Chiara Fenoglio ◽  
Paola Brambilla ◽  
Melissa Sorosina ◽  
Giacomo Giacalone ◽  
...  

BMC Genomics ◽  
2017 ◽  
Vol 18 (1) ◽  
Author(s):  
Tainã Figueiredo Cardoso ◽  
Raquel Quintanilla ◽  
Joan Tibau ◽  
Marta Gil ◽  
Emilio Mármol-Sánchez ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document